SG11202010153WA - Bicyclic carboxamides and methods of use thereof - Google Patents

Bicyclic carboxamides and methods of use thereof

Info

Publication number
SG11202010153WA
SG11202010153WA SG11202010153WA SG11202010153WA SG11202010153WA SG 11202010153W A SG11202010153W A SG 11202010153WA SG 11202010153W A SG11202010153W A SG 11202010153WA SG 11202010153W A SG11202010153W A SG 11202010153WA SG 11202010153W A SG11202010153W A SG 11202010153WA
Authority
SG
Singapore
Prior art keywords
methods
carboxamides
bicyclic
bicyclic carboxamides
Prior art date
Application number
SG11202010153WA
Inventor
Yalda Bravo
Austin Chih-Yu Chen
Jinyue Ding
Robert Gomez
Heather Lam
Joe Fred Nagamizo
Renata Marcella Oballa
David Andrew Powell
Tao Sheng
Original Assignee
Tempest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tempest Therapeutics Inc filed Critical Tempest Therapeutics Inc
Publication of SG11202010153WA publication Critical patent/SG11202010153WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202010153WA 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof SG11202010153WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659068P 2018-04-17 2018-04-17
US201862746843P 2018-10-17 2018-10-17
PCT/US2019/027992 WO2019204523A1 (en) 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202010153WA true SG11202010153WA (en) 2020-11-27

Family

ID=66625250

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010153WA SG11202010153WA (en) 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof

Country Status (12)

Country Link
US (4) US10968201B2 (en)
EP (1) EP3781550A1 (en)
JP (1) JP7361713B2 (en)
KR (1) KR20210003166A (en)
CN (1) CN112313208B (en)
AU (2) AU2019255717B2 (en)
BR (1) BR112020021042A2 (en)
CA (1) CA3096894A1 (en)
IL (1) IL277963B1 (en)
MX (1) MX2020010879A (en)
SG (1) SG11202010153WA (en)
WO (1) WO2019204523A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN110891935B (en) 2017-04-18 2023-12-01 泰普斯特医疗公司 Bicyclic compounds and their use in cancer treatment
IL277963B1 (en) 2018-04-17 2024-05-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN115448913A (en) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases
CN115448882A (en) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases
CN114085167A (en) * 2021-12-13 2022-02-25 华中药业股份有限公司 Preparation method of impurity TS-3A
WO2024102968A1 (en) * 2022-11-10 2024-05-16 Tempest Therapeutics, Inc. Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
CN118164967A (en) * 2022-12-08 2024-06-11 武汉人福创新药物研发中心有限公司 EP2 and EP4 receptor antagonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
BR0316880A (en) 2002-12-23 2005-10-25 Wyeth Corp Pd-1 Antibodies and Uses
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
PT2439273T (en) 2005-05-09 2019-05-13 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2007023028A (en) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd Therapeutic agent for internal ear disease
CN105330741B (en) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2172447A4 (en) * 2007-07-03 2011-08-24 Astellas Pharma Inc Amide compound
RU2479576C9 (en) * 2008-05-14 2014-03-10 Астеллас Фарма Инк. Amide compound
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
CN108484767B (en) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010121385A1 (en) 2009-04-21 2010-10-28 Nortel Networks Limited Method and apparatus for determining channel quality index in multiple user-mimo communication networks
WO2010121382A1 (en) * 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
JP5960597B2 (en) 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター Combined immunotherapy for cancer treatment
JP2013534251A (en) * 2010-08-17 2013-09-02 アラーガン インコーポレイテッド EP2 or EP4 agonists for treating corneal opacity
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TN2015000511A1 (en) 2013-05-23 2017-04-06 Bayer Pharma AG Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
TWI695831B (en) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Compounds as crth2 antagonist and uses thereof
AU2016370779B2 (en) * 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
UY37073A (en) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
HUE057799T2 (en) 2016-07-07 2022-06-28 Ono Pharmaceutical Co Combination comprising ep4 antagonist and immune checkpoint inhibitor
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN110891935B (en) 2017-04-18 2023-12-01 泰普斯特医疗公司 Bicyclic compounds and their use in cancer treatment
IL277963B1 (en) 2018-04-17 2024-05-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof

Also Published As

Publication number Publication date
US20190315712A1 (en) 2019-10-17
US20240150316A1 (en) 2024-05-09
CN112313208B (en) 2024-04-19
US11472789B2 (en) 2022-10-18
AU2023201228A1 (en) 2023-04-06
US20210024491A1 (en) 2021-01-28
US10968201B2 (en) 2021-04-06
BR112020021042A2 (en) 2021-01-19
WO2019204523A1 (en) 2019-10-24
IL277963B1 (en) 2024-05-01
CN112313208A (en) 2021-02-02
IL277963A (en) 2020-11-30
US11795156B2 (en) 2023-10-24
EP3781550A1 (en) 2021-02-24
US20230045612A1 (en) 2023-02-09
AU2019255717B2 (en) 2022-12-08
AU2019255717A1 (en) 2020-11-26
CA3096894A1 (en) 2019-10-24
JP7361713B2 (en) 2023-10-16
KR20210003166A (en) 2021-01-11
MX2020010879A (en) 2020-11-09
JP2021521128A (en) 2021-08-26

Similar Documents

Publication Publication Date Title
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL277963A (en) Bicyclic carboxamides and methods of use thereof
HUE062927T2 (en) Anti-tigit antibodies and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
HUE062436T2 (en) Anti-trem2 antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL271981A (en) Bicyclic ketone compounds and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL289748A (en) Heterodimers and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL283782A (en) Anellosomes and methods of use
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL274221A (en) Anti-apoc3 antibodies and methods of use thereof
IL276053A (en) Therapeutic-gard and method of use thereof
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
IL276792A (en) Inhaler and methods of use thereof
GB202001263D0 (en) Construction apparatus and method of use thereof
EP3849663C0 (en) Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
GB201905100D0 (en) Polypeptides and methods of use